on INTEGRAGEN (EPA:ALINT)
IntegraGen is heading towards receivership to ensure its survival.
On June 15, 2026, IntegraGen, a company specializing in the genomics of cancer and rare genetic diseases, announced the conversion of its safeguard proceedings into receivership. This decision by the Commercial Court of Évry aims to facilitate discussions with several parties interested in its activities. These discussions revealed interest in IntegraGen's expertise, its teams, and its positioning in the clinical genomics market.
The court-ordered restructuring will allow for the exploration of industrial partnerships, acquisitions, or even a takeover, to ensure business continuity and preserve jobs. IntegraGen specifies that its operations are continuing as normal. The company remains in dialogue with stakeholders and will inform the market of any significant developments.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INTEGRAGEN news